The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease

Alper Sonmez, Mahmut Ilker Yilmaz, Mutlu Saglam, Hilmi Umut Unal, Mahmut Gok, Hakki Cetinkaya, Murat Karaman, Cem Haymana, Tayfun Eyileten, Yusuf Oguz, Abdulgaffar Vural, Manfredi Rizzo, Peter P Toth, Alper Sonmez, Mahmut Ilker Yilmaz, Mutlu Saglam, Hilmi Umut Unal, Mahmut Gok, Hakki Cetinkaya, Murat Karaman, Cem Haymana, Tayfun Eyileten, Yusuf Oguz, Abdulgaffar Vural, Manfredi Rizzo, Peter P Toth

Abstract

Background: Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate whether the TG/HDL-C ratio predicts CVD risk in patients with CKD.

Methods: A total of 197 patients (age 53±12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal, observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA), high sensitivity C-reactive protein (CRP), parathyroid hormone (PTH), calcium, phosphorous, estimated glomerular filtration rate (eGFR), and albumin levels were measured. Flow mediated vasodilatation (FMD) of the brachial artery was assessed by using high-resolution ultrasonography.

Results: A total of 11 cardiovascular (CV) deaths and 43 nonfatal CV events were registered in a mean follow-up period of 30 (range 9 to 35) months. Subjects with TG/HDL-C ratios above the median values (>3.29) had significantly higher plasma ADMA, PTH, and phosphorous levels (p=0.04, p=0.02, p=0.01 respectively) and lower eGFR and FMD values (p=0.03, p<0.001 respectively). The TG/HDL-C ratio was an independent determinant of FMD (β=-0.25 p=0.02) along with TG, HDL-C, hsCRP, serum albumin, phosphate levels, systolic blood pressure, PTH, eGFR and the presence of diabetes mellitus. The TG/HDL-C ratio was also a significant independent determinant of cardiovascular outcomes [HR: 1.36 (1.11-1.67) (p=0.003)] along with plasma ADMA levels [HR: 1.31 (1.13-1.52) (p<0.001)] and a history of diabetes mellitus [HR: 4.82 (2.80-8.37) (p<0.001)].

Conclusion: This study demonstrates that the elevated TG/HDL-C ratio predicts poor CVD outcome in subjects with CKD. Being a simple, inexpensive, and reproducible marker of CVD risk, the TG/HDL-C ratio may emerge as a novel and reliable indicator among the many well-established markers of CVD risk in CKD.

Systematic review registration: Clinical trial registration number and date: NCT02113462 / 10-04-2014.

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves according to TG/HDL ratio

References

    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. doi: 10.1056/NEJMoa041031.
    1. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268:456–67. doi: 10.1111/j.1365-2796.2010.02269.x.
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63. doi: 10.1001/archinte.164.6.659.
    1. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease—What have we learned in 10 years? Semin Dial. 2010;23:498–509. doi: 10.1111/j.1525-139X.2010.00784.x.
    1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505–21. doi: 10.2215/CJN.03670807.
    1. Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA. Reverse epidemiology: a confusing, confounding, and inaccurate term. Semin Dial. 2007;20:586–92. doi: 10.1111/j.1525-139X.2007.00366.x.
    1. Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease? Curr Opin Nephrol. 2007;16:506–11. doi: 10.1097/MNH.0b013e3282f0b331.
    1. Hadaegh F, Hatami M, Tohidi M, Sarbakhsh P, Saadat N, Azizi F. Lipid ratios and appropriate cut off values for prediction of diabetes: a cohort of Iranian men and women. Lipids Health Dis. 2010;9:85. doi: 10.1186/1476-511X-9-85.
    1. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029–36. doi: 10.1161/01.CIR.97.11.1029.
    1. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96:399–404. doi: 10.1016/j.amjcard.2005.03.085.
    1. Gasevic D, Frohlich J, Mancini GB, Lear SA. Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study. Lipids Health Dis. 2014;13:159. doi: 10.1186/1476-511X-13-159.
    1. Vega GL, Barlow CE, Grundy SM, Leonard D, Defina LF. Triglyceride-to-High-Density-Lipoprotein-Cholesterol Ratio Is an Index of Heart Disease Mortality and of Incidence of Type 2 Diabetes Mellitus in Men. J Investig Med. 2014;62:345–9.
    1. Onat A, Can G, Kaya H, Hergenç G. “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4:89–98. doi: 10.1016/j.jacl.2010.02.005.
    1. Sung KC, Ryan MC, Kim BS, Cho YK, Kim BI, Reaven GM. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults. Diabetes Care. 2007;30:2113–8. doi: 10.2337/dc07-0512.
    1. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012;11:132. doi: 10.1186/1476-511X-11-132.
    1. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39:S1–266.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70. doi: 10.7326/0003-4819-130-6-199903160-00002.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. doi: 10.1007/BF00280883.
    1. Chen BM, Xia LW, Zhao RQ. Determination of N(G), N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;692:467–71. doi: 10.1016/S0378-4347(96)00531-2.
    1. Haberka M, Mizia-Stec K, Gąsior Z, Mizia M, Janowska J, Holecki M, et al. Serum ADMA concentration – an independent factor determining FMD impairment in cardiac syndrome X. Ups J Med Sci. 2009;114:221–7. doi: 10.3109/03009730903225537.
    1. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–5. doi: 10.1016/0140-6736(92)93147-F.
    1. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65. doi: 10.1016/S0735-1097(01)01746-6.
    1. Kanbay M, Siriopol D, Saglam M, Gulcan Kurt Y, Gok M, Cetinkaya H, et al. Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99(suppl 10):E1854–61. doi: 10.1210/jc.2014-2042.
    1. Saab G, Bomback AS, McFarlane SI, Li S, Chen SC, McCullough PA, et al. The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab. 2012;97:4414–21. doi: 10.1210/jc.2012-2001.
    1. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. Alberta Kidney Disease Network. J Am Soc Nephrol. 2013;24:979–86. doi: 10.1681/ASN.2012080870.
    1. Holzmann MJ, Jungner I, Walldius G, Ivert T, Nordqvist T, Ostergren J, et al. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med. 2012;44:262–70. doi: 10.3109/07853890.2010.532153.
    1. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis. 2001;38:S14–9. doi: 10.1053/ajkd.2001.27384.
    1. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012;60:2372–9. doi: 10.1016/j.jacc.2012.09.013.
    1. Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, et al. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011;103:524–33.
    1. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6. doi: 10.1161/01.CIR.0000103624.14436.4B.
    1. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, et al. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22:1631–41. doi: 10.1681/ASN.2010111144.
    1. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006;99:1–14. doi: 10.1093/qjmed/hci154.
    1. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36. doi: 10.1016/j.jacc.2012.08.1026.
    1. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2014;34:1069–77. doi: 10.1161/ATVBAHA.114.303284.
    1. Décary S, Dumon G, Lamarche B, Hoque JC, Tremblay AJ, Bergeron J, et al. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects. Clin Brioche. 2010;43:401–6. doi: 10.1016/j.clinbiochem.2009.11.010.
    1. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–2. doi: 10.2174/157016111796642698.
    1. Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis. 2000;153:263–72. doi: 10.1016/S0021-9150(00)00603-1.
    1. Kielstein JT, Fliser D. The past, presence and future of ADMA in nephrology. Nephrol Ther. 2007;3:47–54. doi: 10.1016/j.nephro.2007.02.002.
    1. Zoccali C, Yilmaz MI, Mallamaci F. FGF23: a mature renal and cardiovascular risk factor? Blood Purif. 2013;36:52–7. doi: 10.1159/000351001.
    1. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6:785–92. doi: 10.2215/CJN.09231010.
    1. Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of β-cell function and insulin resista nce to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care. 2013;36:2324–30. doi: 10.2337/dc12-0607.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere